STS-135

NameSTS-135
StatusVerified
Submitted2012-10-15
Published2013-02-13
SubmitterPaul D. Kennedy, PhD.
OrganizationCayman Chemical
URLhttps://www.caymanchem.com/catalog/11564
SMILESO=C(NC1(C[C@@H]​2C3)​C[C@H]​(C2)​C[C@H]​3C1)​C4=CN(CCCCCF)​C5=CC=CC=C54
InChIInChI=1S/C24H31FN2O/c25‐8‐4‐1‐5‐9‐27‐16‐21(20‐6‐2‐3‐7‐22(20)27)23(28)26‐24‐13‐17‐10‐18(14‐24)12‐19(11‐ 17)15‐24/h2‐3,6‐7,16‐19H,1,4‐5,8‐15H2,(H,26,28)/t17‐,18+,19‐,24?

STS‐135 is a designer synthetic cannabinoid drug that acts as a potent full agonist of both CB1 and CB2 receptors. The compound possesses a unique carboxamide linkage between the adamantyl side chain and the indole ring that allows it to fall outside of many current state andfederal regulations. STS‐135 contains a 5‐fluoropentyl side chain which is a common modification in the aminoalkylindole series of designer drugs (eg AM2201). The adamantoyl group has been shown to be a CB1 selective agonist, and the adamantyl carboxamide group has been described in the literature and may have an increased affinity for the peripheral CB2 receptor. Similar compounds identified include: AB‐001 (1‐pentyl‐3‐(1‐adamantoyl)indole), JWH 018 adamantyl carboxamide, AM 1248, AKB48, and AKB48‐N‐(5‐fluoropentyl) analog. The origin of the name STS‐135 has not been confirmed but it may be named after the final American Space Shuttle mission, hinting at the product’s psychoactive effects. Evidence exists for the abuse of the adamantoyl series of compounds4 and there are unpublished reports that STS‐135 has been identified in synthetic cannabis samples. There are however, no published reports currently on its pharmacological profile.

Ċ STS-135 Monograph.pdf
View Download
  1320k v. 1 Feb 13, 2013, 1:39 PM Gary Vogt

Committees